Advertisement

Dipeptidyl Peptidase-IV Activity and/or Structure Homologs (DASH): Contributing Factors in the Pathogenesis of Rheumatic Diseases?

  • Eva Balaziova
  • Liliana Sedova
  • Vladislav Mares
  • Kvetoslava Vlasicova
  • Jan Sevcik
  • Aleksi Sedo
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (volume 575)

4. Conclusions

Deregulation of DPP-IV-like activity was observed in synovial fluid and blood plasma of patients with RA and PsA. The cellular source of soluble DPP-IV-like enzymatic activity remains unclear.

Our results suggest significant contribution of intracellular DASH molecules to the total DPP-IV-like enzymatic activity, at least in FMNC from rheumatoid arthritis patients and in BMNC from both rheumatoid arthritis and osteoarthritis.

DASH subcellular distribution was different in FMNC in patients with rheumatoid arthritis compared to degenerative osteoarthritis.

Altered expression pattern and resulting distorted properties of whole DASH enzymatic activity in both systemic—blood—as well as local—joint—environments may impair processing of mediators involved in the inflammatory processes.

Together, DASH molecules, due to their enzymatic activity, may participate on the pathogenesis of RA and PsA and deserve attention as possible future therapeutic targets

Keywords

Rheumatoid Arthritis Psoriatic Arthritis Dipeptidyl Peptidase Inflammatory Rheumatic Disease Altered Expression Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315–324.PubMedGoogle Scholar
  2. Aytac U, Dang NH, 2004, CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord. 4: 11–18.CrossRefPubMedGoogle Scholar
  3. Busek P, Malik R, Sedo A, 2004, Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 36: 408–421.CrossRefPubMedGoogle Scholar
  4. Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M, 2001, Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol. 19: 673–680.PubMedGoogle Scholar
  5. De Meester I, Durinx C, Bal G, Proost P, Struyf S, Goossens F, Augustyns K, Scharpe S, 2000, Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol. 477: 67–87.PubMedCrossRefGoogle Scholar
  6. Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth HU, Brandstetter H, 2003, The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A. 100: 5063–5068.CrossRefPubMedGoogle Scholar
  7. Gladman DD, Stafford-Brady F, Chi-Hsing Chang, Lewandovski K, Russel ML, 1990, Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 17: 809–812.PubMedGoogle Scholar
  8. Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T, 1989, Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem. 35: 1016–1018.PubMedGoogle Scholar
  9. Prevoo ML, van’ t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, 1995, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38: 44–48.PubMedGoogle Scholar
  10. Sedo A, Malik R, 2001, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologos activities? Biochim Biophys Acta. 1550: 107–116.PubMedGoogle Scholar
  11. Sedo A, Malik R, Krepela E, 1998, Dipeptidyl peptidase IV in C6 rat glioma cell line differentiation. Biol Chem. 379: 39–44.PubMedCrossRefGoogle Scholar
  12. Williams YN, Baba H, Hayashi S, Ikai H, Sugita T, Tanaka S, Miyasaka N, Kubota T, 2003, Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin Exp Immunol. 131: 68–74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Eva Balaziova
    • 1
  • Liliana Sedova
    • 2
  • Vladislav Mares
    • 1
  • Kvetoslava Vlasicova
    • 1
  • Jan Sevcik
    • 1
  • Aleksi Sedo
    • 1
  1. 1.Joint Laboratory of Cancer Cell Biology of the 1st Faculty of MedicineCharles University Prague and the Institute of Physiology, Academy of SciencesPrague 2Czech Republic
  2. 2.Institute of RheumatologyPrague 2Czech Republic

Personalised recommendations